In melanomas with activating mutations in the Wnt/β-catenin signaling pathway, C-C chemokine ligand 4 (CCL4) is downregulated, which reduces the migration of CD103+ DCs and leads to a deficiency in CD8+ TILs. This evidence concerns the gene CCL4 and melanoma.